Loading…
Amylyx Pharmaceuticals, Inc. is projected to rise to $21.22 by 2027, a +51% move from its current price of $14.07. AMLX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $13.70 | $14.08 | $14.48 | +0.09% |
| May 30 | $13.56 | $14.10 | $14.66 | +0.18% |
| May 31 | $13.45 | $14.11 | $14.80 | +0.27% |
| Jun 1 | $13.36 | $14.12 | $14.92 | +0.36% |
| Jun 2 | $13.29 | $14.13 | $15.03 | +0.45% |
| Jun 3 | $13.22 | $14.15 | $15.13 | +0.53% |
| Jun 4 | $13.16 | $14.16 | $15.23 | +0.62% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $13.16 | $14.16 | $15.23 | +0.62% |
| Week 2 | $12.85 | $14.25 | $15.79 | +1.25% |
| Week 3 | $12.63 | $14.33 | $16.26 | +1.88% |
| Week 4 | $12.47 | $14.42 | $16.69 | +2.52% |
| Week 5 | $12.33 | $14.51 | $17.08 | +3.16% |
| Week 6 | $12.22 | $14.60 | $17.46 | +3.80% |
| Week 7 | $12.12 | $14.70 | $17.82 | +4.45% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company that engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc.
was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Amylyx Pharmaceuticals, Inc. (AMLX) is currently priced at $13.58 per share with a market capitalization of $1.51B and a rank of 2226. These figures place the stock among mid-cap equities with a clinical-stage focus.
The price outlook is bullish over the longer term, supported by a forecast path that projects rising average prices from 2026 onward, culminating in substantial longer-term upside.
A major floor 32.9% below — a decisive break under it would weaken the trend.
The nearest floor, 9.5% below — buyers have tended to step in here.
The nearest ceiling, 30.5% above — a clean break opens room to run.
A major ceiling 47.0% above — clearing it would confirm fresh momentum.
Key AMLX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AMLX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $13.77 | Buy | $13.78 | Buy |
| MA 10 | $13.62 | Buy | $13.91 | Buy |
| MA 20 | $14.60 | Sell | $14.44 | Sell |
| MA 50 | $15.23 | Sell | $14.90 | Sell |
| MA 100 | $14.69 | Sell | $14.54 | Sell |
| MA 200 | $13.62 | Buy | $13.11 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.07 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | -35.56 | Neutral |
| Williams %R (14) | -45.93 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | -4.48 | Sell |
| Bollinger %B (20,2) | 0.39 | Neutral |
| Stochastic %K (14) | 54.07 | Neutral |
| TRIX (15) | -0.54 | Sell |
| Awesome (5,34) | -1.89 | Sell |
| Ultimate (7,14,28) | 51.45 | Neutral |
| Momentum (10) | -0.37 | Sell |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 13.94 | Buy |
| ADX (14) | 21.90 | Sell |
| ATR (14) | 0.39 | Info |
The 30-day technical picture shows bullish sentiment, with RSI at 40 and key moving averages nearby. The SMA50 sits at $15.24 and the SMA200 sits at $13.55, providing nearby reference points relative to the current price of $13.58. The stock has a defined near-term support at $12.74 and a nearby resistance at $18.36.
In the last 30 days, the price has fluctuated between a low of $11.23 and a high of $16.42, illustrating a contained trading range around the current level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $11.38 | $14.07 | $20.40 | 0% | Neutral | |
| $16.82 | $21.22 | $28.38 | +51% | Bullish | |
| $21.97 | $28.50 | $39.51 | +103% | Bullish | |
| $26.66 | $35.38 | $50.47 | +151% | Bullish | |
| $28.79 | $39.00 | $56.98 | +177% | Bullish | |
| $31.97 | $44.12 | $65.83 | +214% | Bullish | |
| $35.88 | $50.37 | $76.60 | +258% | Bullish | |
| $40.67 | $58.04 | $89.79 | +312% | Bullish | |
| $51.00 | $73.93 | $116.20 | +425% | Bullish | |
| $57.96 | $85.27 | $136.00 | +506% | Bullish | |
| $92.64 | $145.82 | $247.38 | +936% | Bullish | |
| $168.93 | $298.81 | $554.71 | +20.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $11.38 | $14.07 | $16.65 | +0.00% |
| June 2026 | $12.82 | $15.06 | $18.11 | +7.01% |
| July 2026 | $12.88 | $15.26 | $18.60 | +1.34% |
| August 2026 | $12.87 | $15.34 | $18.90 | +0.57% |
| September 2026 | $13.32 | $15.97 | $19.84 | +4.06% |
| October 2026 | $13.49 | $16.26 | $20.36 | +1.84% |
| November 2026 | $13.15 | $15.92 | $20.06 | -2.13% |
| December 2026 | $13.23 | $16.08 | $20.40 | +1.06% |
Click any year to see its month-by-month AMLX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, AMLX could reach as high as $20.40, with a base case around $14.07 and support toward $11.38 — roughly 0% from $14.07. A consolidation phase looks the most probable path here.
Expect AMLX to range from $16.82 to $28.38 through 2027. The $21.22 average target implies a +51% move from current prices. That is up +51% on the projected 2026 average. Momentum favours further upside here.
The AMLX price prediction for 2028 points to an average of $28.50 (low $21.97, high $39.51) — a potential gain of +103% on today's $14.07. Buyers look set to stay in control over this stretch.
In 2029, AMLX is projected to trade between $26.66 and $50.47, averaging $35.38 — a potential gain of +151% from today's $14.07. That is up +24% on the projected 2028 average. Momentum favours further upside here.
Amylyx Pharmaceuticals, Inc.'s 2030 outlook centres on $39.00, within a $28.79 to $56.98 range. That is up +10% on the projected 2029 average. That marks a +177% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, AMLX could reach as high as $65.83, with a base case around $44.12 and support toward $31.97 — roughly +214% from $14.07. Momentum favours further upside here.
Expect AMLX to range from $35.88 to $76.60 through 2032. The $50.37 average target implies a +258% move from current prices. That is up +14% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The AMLX price prediction for 2033 points to an average of $58.04 (low $40.67, high $89.79) — a potential gain of +312% on today's $14.07. Momentum favours further upside here.
In 2034, AMLX is projected to trade between $51.00 and $116.20, averaging $73.93 — a potential gain of +425% from today's $14.07. That is up +27% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Amylyx Pharmaceuticals, Inc.'s 2035 outlook centres on $85.27, within a $57.96 to $136.00 range. That is up +15% on the projected 2034 average. That marks a +506% change versus current levels. Momentum favours further upside here.
By 2040, AMLX could reach as high as $247.38, with a base case around $145.82 and support toward $92.64 — roughly +936% from $14.07. Buyers look set to stay in control over this stretch.
Expect AMLX to range from $168.93 to $554.71 through 2050. The $298.81 average target implies a +20.2x move from current prices. That is up +105% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in AMLX today (≈ 71.073205 AMLX) could be worth
$21,237.67
+$20,237.67 (+2024%) by 2050 · US Dollar
Based on the average projected AMLX price of $298.81 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AMLXwould be worth at today's price.
$1,000 invested in AMLX on May 27, 2025 (≈ 211.864416 AMLX) would be worth
$2,980.93
+$1,980.93 (+198.1%) today · 2.98× · US Dollar
Based on a AMLX entry price of $4.72 vs. today's $14.07.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $13.61 | $1,033.8 | +3.4% |
| 1 month ago | $16.88 | $833.53 | -16.6% |
| 3 months ago | $15.26 | $922.02 | -7.8% |
| 6 months ago | $14.98 | $939.25 | -6.1% |
| 1 year ago | $4.72 | $2,980.93 | +198.1% |
| All time (4.4y) ago | $18.07 | $778.64 | -22.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AMLX forecast.
Our base-case forecast reaches $28.00 around 2028.
Implied market cap at $28.00: $3.11B
The multi-year forecast outlines a clear upward trajectory in average prices and ROI. For 2026, the avg is $13.58 with a 0% ROI and neutral sentiment. The path strengthens into 2027 with an avg of $20.95 and a 54.3% ROI, followed by 2028 at $28.11 with a 107% ROI and 2029 at $35.30 with a 159.9% ROI.
By 2030, the avg is $38.78 and the ROI rises to 185.6%, with bullish sentiment continuing. The forecast extends through 2031–2050, with 2031 avg $43.76 (222.3% ROI), 2032 $50.70 (273.3%), 2033 $58.19 (328.5%), 2034 $74.56 (449.1%), 2035 $87.12 (541.5%), 2040 $149.32 (999.6%), and 2050 $308.09 (2168.7%). These figures imply meaningful upside, though they are estimates, not guarantees.
The upside is framed by bullish sentiment in later years, but as with all clinical-stage equities, notable uncertainty remains.
Tap a question to reveal the answer.
Avg $38.78; min $28.39; max $57.21; ROI 185.6%; sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward with rising averages and ROIs (54.3% in 2027, 107% in 2028, 159.9% in 2029, 185.6% in 2030). These are estimates, not guarantees, and should be weighed with other risk factors.
Yes. The forecast max reaches $118.60 in 2034 and $140.69 in 2035, indicating potential to exceed $100 by 2034.
Current price $13.58; market cap $1.51B; rank 2226.
Avg $149.32; min $93.26; max $256.98; ROI 999.6; sentiment BULLISH.
Amylyx Pharmaceuticals, Inc. Community Discussion
0Share your Amylyx Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.